Search
New MSK research discovered ferroptosis regulators that suggest therapeutic opportunities against hormone receptor-positive cancers; examined how tumor-associated macrophages might be turned against cancer; acquired new insights into joint inflammation in rheumatoid arthritis; developed a systems-level platform called epichaperomics to map changes in interactors among thousands of proteins involved in cancer-related processes; and investigated how artificial intelligence could help diagnose an invasive form of breast cancer.
MSK has joined with 68 of the nation’s top cancer centers in issuing a statement urging increased HPV vaccination for the prevention of cancer. This statement, signed by MSK Physician-in-Chief and Chief Medical Officer José Baslega, MD, PhD, and colleagues at NCI-designated cancer centers across the country, calls upon the nation’s physicians, parents, and young adults to take advantage of this rare opportunity to prevent many types of cancer. MSK head and neck and gynecologic cancer experts are available to discuss the importance of the HPV vaccine and risks of HPV-related cancers. Please email [email protected] to arrange an interview.
Minimally invasive surgery (MIS) to resect liver segments 7 and 8 is safe for select patients treated by experienced MIS hepatopancreatobiliary surgeons.
Researchers have discovered that cancer cells may hijack an immune response to spread from a primary tumor to distant organs.
Michael A. Foley, PhD, has been selected to lead the Tri-Institutional Therapeutics Discovery Institute, Inc., a pioneering collaboration of Weill Cornell Medical College, The Rockefeller University and Memorial Sloan Kettering Cancer Center.
The FDA has approved the first-ever treatment developed for low-grade serous ovarian cancer, a rare type of ovarian cancer.
Learn about how The Society of Memorial Sloan Kettering is supporting precision medicine at MSK Kids.
Androgen deprivation therapy may depress testosterone for prolonged periods in older patients, or those who are on the treatment for more than six months, increasing the risk of associated adverse events, according to the results of our recent retrospective study.
An MSK clinical trial is helping Gail Goode overcome multiple myeloma and sheds new light on how cancer affects people of diverse ethnic backgrounds.
Mutations in a gene called FOXA1 are responsible for a distinct class of prostate cancer tumors, MSK researchers have found.